SCHEMBL23966762

SCHEMBL23966762

Nc1ccc(-c2cn(C3CC(OCc4ccccc4)C3)c3ncnc(N)c23)cc1F

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK2 O43353 2/20 0.62
▸ IGF1R P08069 11/20 0.57
▸ SRC P12931 9/20 0.57
▸ INSR P06213 7/20 0.57
▸ LYN P07948 6/20 0.57
▸ ROCK2 O75116 3/20 0.57
▸ RET P07949 3/20 0.57
▸ ACVR1 Q04771 2/20 0.57
▸ BMPR1B O00238 1/20 0.57
▸ LATS1 O95835 1/20 0.57
▸ YES1 P07947 1/20 0.57
▸ HCK P08631 1/20 0.57
▸ FECH P22830 1/20 0.57
▸ MAP2K2 P36507 1/20 0.57
▸ CSNK1E P49674 1/20 0.57
▸ MAP2K1 Q02750 1/20 0.57
▸ MAP4K2 Q12851 1/20 0.57
▸ STK4 Q13043 1/20 0.57
▸ MAP2K5 Q13163 1/20 0.57
▸ ATR Q13535 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30180719 1.00 RIPK2 (0.62) RIPK2IGF1RSRCINSRLYN
SCHEMBL8930711 0.88 EGFR (0.67) RIPK2IGF1RSRCINSRLYN
SCHEMBL30320537 0.82 PIK3CD (0.52) SRCLYNHCKLCKKDR
SCHEMBL24096503 0.82 PIK3CD (0.52) SRCLYNHCKLCKKDR
SCHEMBL6461714 0.81 RIPK2 (0.68) RIPK2IGF1RSRCINSRLYN
SCHEMBL29998925 0.80 RIPK2 (0.91) RIPK2IGF1RSRCINSRLYN
SCHEMBL23966923 0.80 RIPK2 (0.91) RIPK2IGF1RSRCINSRLYN
SCHEMBL27217870 0.79 IGF1R (0.47) RIPK2IGF1RSRCINSRLYN
SCHEMBL30813404 0.79 IGF1R (0.47) RIPK2IGF1RSRCINSRLYN
SCHEMBL24072895 0.79 IGF1R (0.49) RIPK2IGF1RSRCINSRLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 — — US disclosed
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 — — US disclosed
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 — — US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
CN-115843272-A Inhibitors of NEK7 kinase 哈利亚治疗公司 2023-03-24 — — CN disclosed
WO-2021242505-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. (US) 2021-12-02 — — WO disclosed
US-20210355130-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2021-11-18 — — US disclosed
US-11161852-B1 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2021-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210355130-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 RIPK2 56/4885IGF1R 3045/4885SRC 639/4885
US-11713321-B2 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 RIPK2 56/4885IGF1R 3045/4885SRC 639/4885
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME NEK7, NLRP3, NOD1 RIPK2 23/4885IGF1R 4725/4885SRC 3388/4885
US-11161852-B1 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 RIPK2 56/4885IGF1R 3045/4885SRC 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback